Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

November 16, 2022

Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022

November 1, 2022

Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

October 24, 2022

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

October 12, 2022

Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

August 31, 2022

Enveric Biosciences Appoints New Independent Directors

July 27, 2022

Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

July 26, 2022

Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

July 25, 2022

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

July 19, 2022

Enveric Biosciences Announces Reverse Stock Split

July 14, 2022

‹
1
…
11
12
13
14
15
…
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.